CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Plan Early: Optimizing Stability During Lyophilization
Published on:
Feliza Mirasol
Pharmaceutical Technology, Pharmaceutical Technology, Trends in Manufacturing, May 2022, Volume 2022 eBook, Issue 2
Pages: 22-29
The need for sustainability and early considerations of a lyophilization strategy grow more pertinent on the back of growing biologics volume.
Lyophilization remains an integral step in the manufacturing process for certain biotherapeutics, as was demonstrated with the COVID-19 vaccines. Lyophilization is also important in traditional biologic manufacturing and for emerging therapies. However, there remains inherent risk in subjecting these biomolecules through successive freeze-thaw cycles, which call for best-practice procedures to ensure that product viability and stability are maintained during the lyophilization process. Furthermore, questions have arisen about the long-term sustainability of current lyophilization techniques as the development of new biologic and emerging therapy drug candidates continues to grow.
Advertisement
Reference
1. EC, “EU Legislation to Control F-gases,” ec.europa.eu, accessedJan. 14, 2022.
About the author
Feliza Mirasol is the science editor for Pharmaceutical Technology and Pharmaceutical Technology Europe.
Article details
Pharmaceutical Technology
eBook: Trends in Manufacturing
May 2022
Pages: 22-29
Citation
When referring to this article, please cite it as F. Mirasol, “Plan Early: Optimizing Stability During Lyophilization,” Pharmaceutical Technology Trends in Manufacturing eBook (May 2022).
Related Content:
